Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1549501

Cover Image

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1549501

Tuberculosis Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 6500
PDF (Enterprise License)
USD 9000

Add to Cart

Description

Table of Contents

List of Tables

Tuberculosis therapeutics market is expected to grow at a CAGR of 6.1% during the forecast period of 2024 to 2032, due to rising incidences of TB, increasing awareness about the disease, and advancements in treatment options. TB remains a major global health issue, with active TB being the more severe form requiring immediate treatment, while latent TB needs preventative care. In 2023, active TB treatments generated the highest revenue, attributed to the immediate need for therapeutic intervention. The oral route of administration and tablet dosage form segments led the market in 2023, while the parenteral route and injections segments are projected to witness the highest growth rates. The hospital pharmacy segment held the highest revenue share in 2023, while the online pharmacy segment is expected to achieve the highest CAGR. Geographically, North America dominated the market with the highest revenue share, while the Asia-Pacific region is projected to witness the highest growth rate. The competitive landscape is dominated by leading players such as Sanofi, Pfizer, Johnson & Johnson, and Lupin Limited, focusing on strategic initiatives to maintain their market positions. Overall, the market outlook for TB therapeutics is positive, with significant opportunities for expansion and innovation in the coming years.

Key Market Drivers

Rising Incidence and Prevalence of Tuberculosis

The increasing incidence and prevalence of tuberculosis globally is a significant driver for the TB therapeutics market. TB continues to be a major public health challenge, particularly in developing countries with high population densities and limited access to healthcare. The World Health Organization (WHO) estimates that approximately 10 million people contracted TB in 2023, with a substantial number of cases reported in regions such as Southeast Asia and Sub-Saharan Africa. The high burden of TB in these regions necessitates the development and availability of effective therapeutic options. The rising prevalence of multi-drug-resistant TB (MDR-TB) further exacerbates the situation, requiring more advanced and potent treatment regimens. Pharmaceutical companies are increasingly investing in the development of new drugs and combination therapies to address the growing TB burden. For instance, Johnson & Johnson's Sirturo (bedaquiline) and Pfizer's rifampin are notable drugs that have been instrumental in treating MDR-TB. Additionally, government initiatives and international collaborations aimed at TB eradication, such as the WHO's End TB Strategy, are driving the demand for advanced TB therapeutics. These efforts include extensive screening programs, vaccination drives, and the provision of free or subsidized TB medications, all of which contribute to the growing demand for TB therapeutics.

Technological Advancements in TB Diagnosis and Treatment

Technological advancements in the diagnosis and treatment of tuberculosis have significantly contributed to market growth. Rapid diagnostic tools and molecular tests such as GeneXpert MTB/RIF and Line Probe Assay (LPA) have revolutionized TB detection by providing accurate and quick results, enabling timely initiation of treatment. These advancements have improved the management of TB by allowing healthcare providers to identify drug-resistant strains and tailor treatment regimens accordingly. The development of new therapeutic agents and drug delivery systems has also enhanced the efficacy and safety of TB treatments. For example, the introduction of fixed-dose combination (FDC) therapies has simplified the treatment regimen, improving patient compliance and outcomes. Companies such as Sanofiand Lupin Limited have been at the forefront of developing FDC therapies for TB. Moreover, the advent of nanotechnology and targeted drug delivery systems has opened new avenues for TB treatment. These technologies enhance drug bioavailability and reduce side effects, thereby improving treatment outcomes. The ongoing research and development in the field of TB therapeutics, supported by funding from governments and non-governmental organizations, is expected to drive significant advancements in TB treatment. The integration of digital health technologies and telemedicine for TB management is also gaining traction, facilitating remote monitoring and adherence to treatment protocols, further boosting market growth.

Government and International Initiatives for TB Control

Government and international initiatives for TB control play a crucial role in driving the TB therapeutics market. Various national and international organizations, including the WHO, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Stop TB Partnership, are actively involved in efforts to control and eliminate TB. These initiatives focus on enhancing TB diagnosis, treatment, and prevention, particularly in high-burden countries. The implementation of national TB programs (NTPs) in several countries aims to provide comprehensive TB care, including free diagnosis and treatment services. For instance, the Indian government's National TB Elimination Program (NTEP) aims to achieve TB elimination by 2025 through extensive screening, early diagnosis, and effective treatment. Similarly, the US Centers for Disease Control and Prevention (CDC) supports various TB control programs and research initiatives to combat TB domestically and globally. Funding from international donors and organizations also supports TB control efforts. The Global Fund, for example, provides financial support to countries to strengthen their TB response, improve healthcare infrastructure, and ensure the availability of TB drugs. These initiatives not only enhance access to TB therapeutics but also drive innovation and development of new treatment options. The increased focus on TB control by governments and international bodies is expected to sustain the demand for TB therapeutics, fostering market growth over the forecast period.

Restraint

High Cost of TB Treatment

The high cost of TB treatment poses a significant restraint to the market. Despite advancements in TB therapeutics, the treatment regimens, especially for MDR-TB and extensively drug-resistant TB (XDR-TB), are expensive and often unaffordable for patients in low- and middle-income countries. The cost of drugs, diagnostic tests, and the prolonged duration of treatment contribute to the financial burden on patients and healthcare systems. For instance, the treatment for MDR-TB can cost up to 20 times more than the standard treatment for drug-susceptible TB. The high cost of newer TB drugs such as bedaquiline and delamanid further exacerbates the affordability issue. Additionally, the lack of health insurance coverage and financial support in many high-burden countries limits access to effective TB treatment. The economic burden of TB treatment affects not only patients but also national healthcare budgets, hindering efforts to scale up TB control programs. To address this restraint, there is a need for increased funding from governments and international organizations to subsidize the cost of TB treatment and ensure affordability and accessibility for all patients.

Market Segmentation by Disease Type

The tuberculosis therapeutics market is segmented by disease type into active TB and latent TB. In 2023, active TB treatments generated the highest revenue due to the immediate need for therapeutic intervention and the higher costs associated with treating active infections. Active TB requires a combination of antibiotics over an extended period, often involving first-line and second-line therapies, contributing to higher treatment costs. Companies such as Pfizer and Johnson & Johnson have developed effective drugs for active TB treatment, including rifampin and bedaquiline. However, during the forecast period of 2024 to 2032, the latent TB segment is expected to exhibit the highest CAGR. The growing emphasis on TB prevention and early diagnosis drives this growth. Latent TB treatment aims to prevent the progression to active TB, particularly in high-risk populations such as people living with HIV and those with compromised immune systems. The increased implementation of TB screening programs and preventive therapy initiatives by governments and healthcare organizations is expected to boost the demand for latent TB therapeutics. For example, the CDC recommends latent TB infection testing and treatment for high-risk groups in the US, contributing to the growing market for latent TB therapeutics. The shift towards preventive healthcare and the focus on reducing the global TB burden is anticipated to drive significant growth in the latent TB segment.

Market Segmentation by Therapy

The market segmentation by therapy includes first-line therapy and second-line therapy. In 2023, first-line therapy accounted for the highest revenue, attributed to its widespread use as the standard treatment for drug-susceptible TB. First-line therapy typically involves a combination of antibiotics such as isoniazid, rifampin, ethambutol, and pyrazinamide, administered over six to nine months. These drugs are highly effective and are the preferred choice for treating new and uncomplicated TB cases. The affordability and availability of first-line drugs in both high-income and low-income countries contribute to their dominance in the market. However, during the forecast period of 2024 to 2032, second-line therapy is expected to achieve the highest CAGR. The rising incidence of MDR-TB and XDR-TB, which are resistant to first-line drugs, drives the demand for second-line therapy. Second-line treatment involves more potent and expensive drugs such as fluoroquinolones and injectable agents, administered over a longer duration, often exceeding 20 months. The complexity and higher cost of second-line therapy contribute to its rapid market growth. Pharmaceutical companies are investing in the development of new second-line drugs and combination therapies to address the challenges of drug-resistant TB. For instance, Johnson & Johnson's bedaquiline and Otsuka Pharmaceutical's delamanid are notable second-line drugs that have significantly improved the treatment outcomes for MDR-TB. The growing focus on combating drug-resistant TB and the development of novel therapeutic options are expected to drive significant growth in the second-line therapy segment.

Market Segmentation by Route of Administration

The tuberculosis therapeutics market is segmented by the route of administration into oral, parenteral, and others. In 2023, the oral segment generated the highest revenue, driven by the convenience, ease of administration, and high patient compliance associated with oral medications. Oral administration is the preferred route for most TB drugs, including first-line and second-line therapies. Companies such as Pfizer and Lupin Limited offer a range of oral TB medications, including tablets and capsules, that are widely used in TB treatment. The affordability and availability of oral drugs, particularly in resource-limited settings, contribute to their dominance in the market. However, during the forecast period of 2024 to 2032, the parenteral segment is expected to exhibit the highest CAGR. Parenteral administration, which includes intravenous and intramuscular injections, is primarily used for second-line TB drugs and in cases where oral administration is not feasible. The increasing prevalence of MDR-TB and the need for more effective drug delivery methods drive the demand for parenteral TB therapeutics. Injectable agents such as kanamycin and capreomycin are commonly used in second-line therapy for MDR-TB. The development of new parenteral formulations and drug delivery technologies further enhances the efficacy and safety of TB treatments. The growing focus on improving treatment outcomes for drug-resistant TB and the advancements in injectable drug formulations are expected to drive significant growth in the parenteral segment.

Market Segmentation by Dosage Form

The market segmentation by dosage form includes tablets, capsules, injections, and others. In 2023, the tablets segment accounted for the highest revenue, attributed to the widespread use of tablet formulations in TB treatment. Tablets are the preferred dosage form for most first-line and second-line TB drugs, offering ease of administration, accurate dosing, and high patient compliance. Companies such as Sanofi and Lupin Limited provide a range of TB medications in tablet form, including fixed-dose combinations that simplify the treatment regimen. The affordability and availability of tablet formulations, particularly in low-income and middle-income countries, contribute to their dominance in the market. However, during the forecast period of 2024 to 2032, the injections segment is expected to achieve the highest CAGR. Injections are primarily used for second-line TB drugs and in cases where oral administration is not feasible. The increasing prevalence of MDR-TB and the need for more effective drug delivery methods drive the demand for injectable TB therapeutics. Injectable agents such as streptomycin and amikacin are commonly used in second-line therapy for MDR-TB. The development of new injectable formulations and drug delivery technologies further enhances the efficacy and safety of TB treatments. The growing focus on improving treatment outcomes for drug-resistant TB and the advancements in injectable drug formulations are expected to drive significant growth in the injections segment.

Market Segmentation by Distribution Channel

The tuberculosis therapeutics market is segmented by distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy. In 2023, the hospital pharmacy segment generated the highest revenue, driven by the high volume of TB drugs dispensed through hospital pharmacies. Hospitals are the primary points of care for TB patients, particularly in high-burden countries, and play a crucial role in TB diagnosis and treatment. Hospital pharmacies ensure the availability of essential TB medications and provide comprehensive care for TB patients. Companies such as Pfizer and Johnson & Johnson distribute their TB drugs through hospital pharmacies, ensuring accessibility for patients. However, during the forecast period of 2024 to 2032, the online pharmacy segment is expected to exhibit the highest CAGR. The growing adoption of digital health technologies and e-commerce platforms drives the demand for online pharmacies. Online pharmacies offer convenience, ease of access, and home delivery of TB medications, particularly in remote and underserved areas. The increasing internet penetration and the rising trend of online healthcare services contribute to the growth of the online pharmacy segment. Companies are leveraging online platforms to expand their reach and provide TB medications to a broader patient population. The growing focus on improving access to TB medications and the advancements in digital health technologies are expected to drive significant growth in the online pharmacy segment.

Geographic Trends

The tuberculosis therapeutics market exhibits significant geographic variations, with North America and Asia-Pacific being the key regions driving market growth. In 2023, North America held the highest revenue percentage, attributed to the advanced healthcare infrastructure, high awareness about TB, and the presence of leading pharmaceutical companies. The US, in particular, has a well-established TB control program, supported by government initiatives and funding. The availability of advanced diagnostic tools and effective treatment options contributes to the high revenue share of North America. However, during the forecast period of 2024 to 2032, the Asia-Pacific region is expected to witness the highest CAGR. The high burden of TB in countries such as India, China, and Indonesia, coupled with the increasing focus on TB control and prevention, drives the demand for TB therapeutics in the region. Government initiatives, international collaborations, and funding from organizations such as the WHO and the Global Fund support TB control efforts in Asia-Pacific. The implementation of national TB programs, extensive screening campaigns, and the availability of free or subsidized TB medications contribute to the market growth. The growing healthcare infrastructure, increasing awareness about TB, and the rising focus on preventive healthcare are expected to drive significant growth in the Asia-Pacific region.

Competitive Trends

The competitive landscape of the tuberculosis therapeutics market is dominated by key players such as Sanofi, Pfizer, Johnson & Johnson, Lupin Limited, AstraZeneca, Eli Lilly and Company, Viatris Inc. (Mylan N.V.), Teva Pharmaceutical Industries, Ltd., Novartis AG, and Sun Pharmaceutical Industries Ltd., who focus on strategic initiatives to strengthen their market positions. In 2023, these companies generated significant revenues from their TB drug offerings, leveraging their extensive product portfolios and strong market presence. Sanofi, known for its commitment to TB eradication, offers a range of TB medications, including fixed-dose combinations for first-line therapy. Pfizer, with its expertise in infectious diseases, provides effective TB drugs such as rifampin and pyrazinamide. Johnson & Johnson's bedaquiline has been instrumental in treating MDR-TB, while Lupin Limited offers a comprehensive range of TB medications, including second-line drugs. These companies employ strategies such as mergers and acquisitions, product innovations, and market expansions to maintain their competitive edge. For instance, Johnson & Johnson has focused on expanding its TB drug portfolio and enhancing production capabilities to meet the growing demand for effective TB treatments. Pfizer invests in research and development to develop innovative TB drugs that cater to the evolving needs of TB patients. Lupin Limited emphasizes quality assurance and compliance with international standards, ensuring that its TB medications meet the highest industry standards. The continuous focus on innovation, coupled with strategic collaborations and investments, defines the competitive dynamics of the TB therapeutics market. As the market evolves and new players enter the industry, the competitive landscape is expected to become more dynamic, driving further advancements and growth in the TB therapeutics market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Tuberculosis Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Tuberculosis Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Disease

    • Active TB
    • Latent TB

Therapy

    • First-Line Therapy
    • Second-Line Therapy

Route of Administration

    • Oral
    • Parenteral
    • Others

Dosage

    • Tablets
    • Capsules
    • Injection
    • Others

Distribution

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Tuberculosis Therapeutics market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Tuberculosis Therapeutics market?

Which is the largest regional market for Tuberculosis Therapeutics market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Tuberculosis Therapeutics market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Tuberculosis Therapeutics market worldwide?

Show more
Product Code: 140393-08-24

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Tuberculosis Therapeutics Market
  • 2.2. Global Tuberculosis Therapeutics Market, By Disease, 2023 (US$ Million)
  • 2.3. Global Tuberculosis Therapeutics Market, By Therapy, 2023 (US$ Million)
  • 2.4. Global Tuberculosis Therapeutics Market, By Route of Administration, 2023 (US$ Million)
  • 2.5. Global Tuberculosis Therapeutics Market, By Dosage, 2023 (US$ Million)
  • 2.6. Global Tuberculosis Therapeutics Market, By Distribution, 2023 (US$ Million)
  • 2.7. Global Tuberculosis Therapeutics Market, By Geography, 2023 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2023

3. Tuberculosis Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Tuberculosis Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Tuberculosis Therapeutics Market Vendors
  • 3.3. Key Industry Strategies

4. Tuberculosis Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Tuberculosis Therapeutics Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Active TB
    • 5.3.2. Latent TB

6. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. First-Line Therapy
    • 6.3.2. Second-Line Therapy

7. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others

8. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 8.3. Market Segmentation
    • 8.3.1. Tablets
    • 8.3.2. Capsules
    • 8.3.3. Injection
    • 8.3.4. Others

9. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 9.3. Market Segmentation
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy

10. North America Tuberculosis Therapeutics Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
  • 10.3. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
  • 10.4. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
  • 10.5. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
  • 10.6. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
  • 10.7.Tuberculosis Therapeutics Market: By Region, 2022-2032, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 10.7.1.1.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 10.7.1.1.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.7.1.1.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 10.7.1.1.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 10.7.1.2.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 10.7.1.2.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.7.1.2.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 10.7.1.2.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 10.7.1.3.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 10.7.1.3.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.7.1.3.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 10.7.1.3.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

11. UK and European Union Tuberculosis Therapeutics Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
  • 11.3. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
  • 11.4. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
  • 11.5. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
  • 11.6. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
  • 11.7.Tuberculosis Therapeutics Market: By Region, 2022-2032, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.1.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.1.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.1.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.1.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.2.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.2.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.2.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.2.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.3.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.3.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.3.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.3.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.4.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.4.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.4.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.4.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.5.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.5.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.5.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.5.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 11.7.1.6.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 11.7.1.6.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.7.1.6.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 11.7.1.6.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

12. Asia Pacific Tuberculosis Therapeutics Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
  • 12.3. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
  • 12.4. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
  • 12.5. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
  • 12.6. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
  • 12.7.Tuberculosis Therapeutics Market: By Region, 2022-2032, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.1.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.1.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.1.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.1.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.2.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.2.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.2.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.2.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.3.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.3.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.3.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.3.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.4.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.4.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.4.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.4.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.5.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.5.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.5.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.5.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 12.7.1.6.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 12.7.1.6.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.7.1.6.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 12.7.1.6.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

13. Latin America Tuberculosis Therapeutics Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
  • 13.3. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
  • 13.4. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
  • 13.5. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
  • 13.6. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
  • 13.7.Tuberculosis Therapeutics Market: By Region, 2022-2032, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 13.7.1.1.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 13.7.1.1.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.7.1.1.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 13.7.1.1.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 13.7.1.2.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 13.7.1.2.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.7.1.2.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 13.7.1.2.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 13.7.1.3.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 13.7.1.3.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.7.1.3.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 13.7.1.3.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

14. Middle East and Africa Tuberculosis Therapeutics Market, 2022-2032, USD (Million)

  • 14.1. Market Overview
  • 14.2. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
  • 14.3. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
  • 14.4. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
  • 14.5. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
  • 14.6. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
  • 14.7.Tuberculosis Therapeutics Market: By Region, 2022-2032, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 14.7.1.1.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 14.7.1.1.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 14.7.1.1.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 14.7.1.1.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 14.7.1.2.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 14.7.1.2.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 14.7.1.2.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 14.7.1.2.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Tuberculosis Therapeutics Market: By Disease, 2022-2032, USD (Million)
        • 14.7.1.3.2. Tuberculosis Therapeutics Market: By Therapy, 2022-2032, USD (Million)
        • 14.7.1.3.3. Tuberculosis Therapeutics Market: By Route of Administration, 2022-2032, USD (Million)
        • 14.7.1.3.4. Tuberculosis Therapeutics Market: By Dosage, 2022-2032, USD (Million)
        • 14.7.1.3.5. Tuberculosis Therapeutics Market: By Distribution, 2022-2032, USD (Million)

15. Company Profile

  • 15.1. Sanofi
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Pfizer
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. Johnson & Johnson
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. Lupin Limited
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. AstraZeneca
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Eli Lilly and Company
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. Viatris Inc. (Mylan N.V.)
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. Teva Pharmaceutical Industries, Ltd.
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. Novartis AG
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. Sun Pharmaceutical Industries Ltd.
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives
  • 15.11. Other Notable Players
    • 15.11.1. Company Overview
    • 15.11.2. Financial Performance
    • 15.11.3. Product Portfolio
    • 15.11.4. Strategic Initiatives
Show more
Product Code: 140393-08-24

List of Tables

  • TABLE 1 Global Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 2 Global Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 3 Global Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 4 Global Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 5 Global Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 6 North America Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 7 North America Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 8 North America Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 9 North America Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 10 North America Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 11 U.S. Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 12 U.S. Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 13 U.S. Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 14 U.S. Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 15 U.S. Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 16 Canada Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 17 Canada Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 18 Canada Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 19 Canada Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 20 Canada Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 21 Rest of North America Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 22 Rest of North America Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 23 Rest of North America Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 24 Rest of North America Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 25 Rest of North America Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 26 UK and European Union Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 27 UK and European Union Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 28 UK and European Union Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 29 UK and European Union Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 30 UK and European Union Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 31 UK Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 32 UK Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 33 UK Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 34 UK Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 35 UK Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 36 Germany Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 37 Germany Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 38 Germany Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 39 Germany Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 40 Germany Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 41 Spain Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 42 Spain Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 43 Spain Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 44 Spain Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 45 Spain Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 46 Italy Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 47 Italy Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 48 Italy Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 49 Italy Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 50 Italy Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 51 France Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 52 France Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 53 France Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 54 France Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 55 France Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 56 Rest of Europe Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 57 Rest of Europe Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 58 Rest of Europe Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 59 Rest of Europe Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 60 Rest of Europe Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 61 Asia Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 62 Asia Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 63 Asia Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 64 Asia Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 65 Asia Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 66 China Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 67 China Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 68 China Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 69 China Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 70 China Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 71 Japan Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 72 Japan Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 73 Japan Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 74 Japan Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 75 Japan Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 76 India Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 77 India Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 78 India Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 79 India Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 80 India Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 81 Australia Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 82 Australia Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 83 Australia Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 84 Australia Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 85 Australia Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 86 South Korea Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 87 South Korea Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 88 South Korea Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 89 South Korea Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 90 South Korea Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 91 Latin America Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 92 Latin America Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 93 Latin America Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 94 Latin America Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 95 Latin America Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 96 Brazil Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 97 Brazil Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 98 Brazil Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 99 Brazil Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 100 Brazil Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 101 Mexico Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 102 Mexico Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 103 Mexico Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 104 Mexico Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 105 Mexico Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 106 Rest of Latin America Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 107 Rest of Latin America Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 108 Rest of Latin America Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 109 Rest of Latin America Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 110 Rest of Latin America Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 111 Middle East and Africa Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 112 Middle East and Africa Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 113 Middle East and Africa Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 114 Middle East and Africa Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 115 Middle East and Africa Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 116 GCC Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 117 GCC Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 118 GCC Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 119 GCC Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 120 GCC Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 121 Africa Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 122 Africa Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 123 Africa Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 124 Africa Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 125 Africa Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)
  • TABLE 126 Rest of Middle East and Africa Tuberculosis Therapeutics Market By Disease, 2022-2032, USD (Million)
  • TABLE 127 Rest of Middle East and Africa Tuberculosis Therapeutics Market By Therapy, 2022-2032, USD (Million)
  • TABLE 128 Rest of Middle East and Africa Tuberculosis Therapeutics Market By Route of Administration, 2022-2032, USD (Million)
  • TABLE 129 Rest of Middle East and Africa Tuberculosis Therapeutics Market By Dosage, 2022-2032, USD (Million)
  • TABLE 130 Rest of Middle East and Africa Tuberculosis Therapeutics Market By Distribution, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Tuberculosis Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Tuberculosis Therapeutics Market: Quality Assurance
  • FIG. 5 Global Tuberculosis Therapeutics Market, By Disease, 2023
  • FIG. 6 Global Tuberculosis Therapeutics Market, By Therapy, 2023
  • FIG. 7 Global Tuberculosis Therapeutics Market, By Route of Administration, 2023
  • FIG. 8 Global Tuberculosis Therapeutics Market, By Dosage, 2023
  • FIG. 9 Global Tuberculosis Therapeutics Market, By Distribution, 2023
  • FIG. 10 Global Tuberculosis Therapeutics Market, By Geography, 2023
  • FIG. 11 Market Geographical Opportunity Matrix - Global Tuberculosis Therapeutics Market, 2023

FIG. 12Market Positioning of Key Tuberculosis Therapeutics Market Players, 2023

FIG. 13Global Tuberculosis Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 14 Global Tuberculosis Therapeutics Market, By Disease, 2023 Vs 2032, %
  • FIG. 15 Global Tuberculosis Therapeutics Market, By Therapy, 2023 Vs 2032, %
  • FIG. 16 Global Tuberculosis Therapeutics Market, By Route of Administration, 2023 Vs 2032, %
  • FIG. 17 Global Tuberculosis Therapeutics Market, By Dosage, 2023 Vs 2032, %
  • FIG. 18 Global Tuberculosis Therapeutics Market, By Distribution, 2023 Vs 2032, %
  • FIG. 19 U.S. Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 20 Canada Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 21 Rest of North America Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 22 UK Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 23 Germany Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 24 Spain Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 25 Italy Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 26 France Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 27 Rest of Europe Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 28 China Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 29 Japan Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 30 India Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 31 Australia Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 32 South Korea Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 33 Rest of Asia Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 34 Brazil Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 35 Mexico Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 36 Rest of Latin America Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 37 GCC Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 38 Africa Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
  • FIG. 39 Rest of Middle East and Africa Tuberculosis Therapeutics Market (US$ Million), 2022 - 2032
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!